Barcelona Liver Bioservices (BLB) announced today a non-exclusive partnership with the biopharmaceutical company Gilead Sciences to characterize the effects of novel chemical entities developed by Gilead for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH).

“We are eager about our collaboration with Gilead” said Jordi Gracia-Sancho, BLB’s chief scientific officer. “Gilead has recognized the value and potential of our complete pre-clinical solution to accelerate the development of new therapeutics for liver diseases”.

Under the terms of the agreement, BLB will combine its diverse pre-clinical models of liver disease, including the BLB proprietary platform ExoLiver®, to ascertain the efficacy and the underlying molecular mechanisms of Gilead’s best-in-class compounds as novel treatments for chronic liver disease and NASH.

For more information about the services and research developed by BLB please visit www.liver.barcelona

Barcelona Liver Bioservices (BLB), CRO specialized in the design and development of pre-clinical research in hepatology, announced today a non-exclusive partnership with BrudyLab to explore Brudy’s lead compound DHA as novel therapeutic option for liver disease.

In the initial phase of the collaboration, BLB will investigate the effects and underlying mechanisms of Brudy-DHA in pre-clinical models of chronic liver disease.

For more information about the services and research developed by BLB please visit www.liver.barcelona